CHMP positive opinion on Eylea will stir up EU AMD market
This article was originally published in Scrip
Experts on the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) are recommending that the European Commission gives marketing approval for Eylea (aflibercept) as a treatment of neovascular (wet) age-related macular degeneration (AMD). The recombinant anti-VEGF fusion protein has already been approved for the same indication by the FDA (scripintelligence.com, 21 November, 2011), Australia (March 2012) and Japan (scripintelligence.com, 4 September, 2012). Eylea is currently in a Phase III clinical study for wet AMD in China (scripintelligence.com, 29 November, 2011).